Don't Go There: A Geospatial mHealth App for Gambling Disorder

August 20, 2025 updated by: Jeremiah Weinstock, St. Louis University
The goal of this project is to develop and to test the efficacy of a novel mHealth app for gambling disorder. The app capitalizes on smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. Users will receive an alert of this go near a gambling venue. The project will conduct a 12-week pilot randomized clinical trial to test the short-term efficacy of the app with gambling disorder individuals.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • St Louis, Missouri, United States, 63108
        • Saint Louis University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Currently meets DSM-5 criteria for gambling disorder
  • At least 4 non-online gambling episodes in past 60 days
  • Wagering at least $100 total over past 60 days
  • Willingness to accept random assignment
  • English speaking
  • Android phone user

Exclusion Criteria:

  • Age <18 years old
  • Severely disruptive behavior
  • Serious uncontrolled psychiatric behavior that requires acute psychiatric care
  • Decline permission to collect zero permission data from smartphone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: mHealth App
Participants will receive the gambling disorder mHealth app.
The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
No Intervention: Wait List Control
Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
App usage (feasibility)
Time Frame: From baseline to post-treatment (12 weeks)
Number of days the app is active on a user's smartphone. Days can range from 0 to 84.
From baseline to post-treatment (12 weeks)
Patient satisfaction with the gambling app
Time Frame: From baseline to post-treatment (12 weeks)
Investigator derived patient satisfaction self-report questionnaire. Five items, using a 7-point Likert scale from very dissatisfied (1) to very satisfied (7). Higher scores indicate a better outcome.
From baseline to post-treatment (12 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gambling behavior via Timeline Followback (Weinstock, Whelan, & Meyers, 2004)
Time Frame: From baseline to post-treatment (12 weeks)
Self-report gambling frequency and intensity as assessed by the Gambling Timeline Followback - a retrospective self-report calendar. Gambling frequency can range from 0 to 84; gambling intensity is measured in $ and time (hours). Dollars wagered can range from $0 to unlimited $. Time is measured in hours and can range from 0 to >1,000 hours. Higher scores indicate a worse outcome.
From baseline to post-treatment (12 weeks)
Gambling-related harms (Browne et al., 2018)
Time Frame: From baseline to post-treatment (12 weeks)
Self-reported gambling harms as assessed by the 72-item Gambling-Related Harms Questionnaire (yes/no responses). Scores range from 0 to 72. Higher scores indicate a worse outcome.
From baseline to post-treatment (12 weeks)
Quality of Life Inventory (Frisch et al., 1994). A self-reported quality of life measure assessing 17 domains of life for importance and satisfaction.
Time Frame: From baseline to post-treatment (12 weeks)
Self-report quality of life questionnaire. Participants rate 17 domains on importance (range not at all important [0] to extremely important [2]). The 17 domains are then rated on how satisfied the individual is regards to his or her life (-3 [very dissatisfied] to 3 [very dissatisfied]). A total score is then generated by summing the product of importance multiplied by satisfaction. Scores range from 0 to 102. Higher scores indicate a better outcome.
From baseline to post-treatment (12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jeremiah Weinstock, PhD, St. Louis University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 31, 2024

Primary Completion (Actual)

May 31, 2025

Study Completion (Actual)

June 1, 2025

Study Registration Dates

First Submitted

November 5, 2019

First Submitted That Met QC Criteria

November 7, 2019

First Posted (Actual)

November 8, 2019

Study Record Updates

Last Update Posted (Estimated)

August 27, 2025

Last Update Submitted That Met QC Criteria

August 20, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 30494

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gambling Disorder

Clinical Trials on mHealth App

Subscribe